LB Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
LB Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing novel, small-molecule therapies for the treatment of neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder (MDD). The company's lead product candidate is LB-102 (N-methyl amisulpride), a novel, once-daily, orally administered selective dopamine D2/D3 and 5-HT7 receptor antagonist. LB-102 is designed as a methylated derivative of amisulpride—a second-generation antipsychotic widely used in Europe but never approved in the United States. This subtle structural modification enhances blood-brain barrier permeability, allowing for lower therapeutic doses and once-daily dosing, with the goal of minimizing side effects and improving patient adherence.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead product candidate, LB-102 (a methylated derivative of amisulpride), into the pivotal Phase 3 NOVA-2 trial to evaluate its efficacy, safety, and cognitive benefits in patients with acute schizophrenia.
Expected impact: Establish LB-102 as the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States, offering a class-leading safety and cognitive profile.
Expanding the clinical utility of LB-102 beyond schizophrenia into mood disorders, specifically targeting bipolar depression and major depressive disorder (MDD).
Expected impact: Unlock the full therapeutic and commercial potential of LB-102 across a broader neuropsychiatric portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborated as a key investment bank and placement agent to execute the company's $327.8 million upsized IPO in September 2025 and the subsequent $100 million private placement in February 2026.
Terms: Underwriting and placement agent fees associated with the capital raises.